Overview

AflacLL1901 (CHOA-AML)

Status:
Terminated

Trial end date:
2021-05-19

Target enrollment:

Participant gender:

Summary

The investigators propose to study an Aflac-AML chemotherapy backbone prospectively to validate its use in all pediatric AML and to further evaluate the cardiotoxicity with this approach for low risk AML.

Phase:

Phase 2

Details

Lead Sponsor:

Emory University

Treatments:

Asparaginase
Calicheamicins
Cytarabine
Daunorubicin
Etoposide
Gemtuzumab
Sorafenib